IFPMA announces Sunao Manabe as new Vice President
Sunao Manabe – IFPMA Vice President, President and Chief Executive Officer at Daiichi Sankyo
Today, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced Sunao Manabe, President and Chief Executive Officer (CEO) at Daiichi Sankyo, as IFPMA Vice President.
IFPMA President and CEO of UCB, Jean-Christophe Tellier welcomes Sunao Manabe, President and CEO of Daiichi Sankyo to IFPMA leadership team. “I am thrilled Sunao will join IFPMA’s leadership team,” said Jean-Christophe. “As a highly respected industry leader committed to improving global health, he is deeply committed to innovation and partnerships which is critical to IFPMA’s mission of engaging with key stakeholders to co-create sustainable solutions to strengthen health systems and address global health challenges.”
“The ongoing threat of COVID-19 throughout 2021 reinforced for me the fact that improving human health around the world is an essential part of sustainable social development. I look forward to bringing my insights to help support IFPMA in its efforts to support a sustainable & ethical biopharmaceutical business model to enable impactful innovation for society as well as its availability & accessibility” said Sunao Manabe, chief executive of Daiichi Sankyo.
The ongoing threat of COVID-19 throughout 2021 reinforced for me the fact that improving human health around the world is an essential part of sustainable social development.
Sunao Manabe has served as President of Daiichi Sankyo since 2017 and in 2019, he was appointed in addition to CEO of Daiichi Sankyo, one of Japan’s leading biopharmaceutical companies. He was appointed to serve as Vice President of the Japan Pharmaceutical Manufacturers Association (JPMA) in 2021.
Sunao Manabe has been with Daiichi Sankyo since it was established in 2005 through the merger Daiichi Pharmaceutical Company and of Sankyo Company, where he started his career in 1978. With more than 100 years of scientific expertise and a presence in more than 25 countries, Daiichi Sankyo is a leading global innovation pharmaceutical company, with 16,000 employees around the world drawing upon a rich legacy of innovation and a robust pipeline of promising new medicines.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
